Biotech Values

[tinkershaw]

EXEL phase II.news unimpressive i assume?

These phase II results were interesting, but nothing like previous results in other indications.

What it does show, is more proof of concept (I guess) that this drug is for real. Its effectiveness is different in different indications, but it has shown too many results, in too many different settings, to think that the drug is not real in that it has real and material medicinal benefit and not some false positive reading. Tbd in regard to degree of said effectiveness, and in regard to comparison to competitive agents, and differentiation from competitive agents.

I think the share price crash was well over done, as it had nothing to do with any science but rather with a regulatory decision which importance was exaggerated. Said usually makes for the characteristic biotech come back, for those with sufficient patience.

But these phase II results are not such (if this were all there was) that would be exciting, but would be sufficient to move it forward if this were a small biotech and all the drug had going for it, but that is not the case here. Whether or not EXEL pushes it forward in this indication with these results...I don't think it will be a high priority, but perhaps in the future when (if fortunate enough) Exel and its partner are mid-life cycle managing the drug.

Tinker